All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Treatment for relapsed/refractory acute myeloid leukemia (AML) remains a challenge due to reduced efficacy and high rates of complications related to disease-associated cytopenia. There have been promising results with venetoclax plus azacitidine or low-dose cytarabine (LDAC) at measurable residual disease (MRD) relapse; however, most studies have been retrospective.
Recently, Tiong et al.1 published results from the phase II VALDAC study (ACTRN12619000746134) in Journal of Clinical Oncology investigating the outcomes of venetoclax + LDAC in patients with AML and either MRD or oligoblastic relapse. Here we summarize the key findings.
Figure 1. Response rates in patients with AML treated with venetoclax + LDAC who had either MRD or oligoblastic relapse*
MRD, measurable residual disease.
*Adapted from Tiong, et al.1
†Response in the MRD cohort was defined as an MRD response.
‡Response in the oligoblastic cohort was defined as a hematologic response (complete remission [CR]/CR with partial hematologic recovery/CR with incomplete recovery).
Key learnings |
---|
|
Subscribe to get the best content related to AML delivered to your inbox